<DOC>
	<DOCNO>NCT02582840</DOCNO>
	<brief_summary>This randomize , single-blind , 3 arm , parallel group , placebo control PK/PD study enrol 30 Japanese male female patient T1DM age 18 65 year , inadequate glycemic control insulin define HbA1c ≥ 7.0 % ≤ 10.0 % screen visit . lacebo-controlled design . Patients randomize 1:1:1 ratio one 3 single-blinded treatment arm ; dapagliflozin 5 mg , dapagliflozin 10 mg placebo . CSII user exclude .</brief_summary>
	<brief_title>The PK PD Dapagliflozin Therapy Combination With Insulin Japanese Subjects With T1DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Signed Written Informed Consent Subjects legally responsible representative must willing able give sign date write informed consent . Target Population Diagnosis T1DM . In addition , follow criterion also need meet ; Central laboratory test Cpeptide &lt; 0.7 ng/mL Subject reenrolment : This study permit reenrolment subject discontinue study screen failure Insulin use least 12 month prior enrolment per subject report medical record Method insulin administration ( MDI ) must unchanged least 3 month prior enrolment per subject report medical record . Subjects must take total daily insulin dose ≥ 0.3 U/kg/day least 3 month prior enrolment . CSII user exclude . MDI insulin administration subject must ≥ 3x injection per day . Gender reproductive Status Japanese men woman . HbA1c eligibility criterion include : Screening Visit : Central laboratory HbA1c ≥ 7.0 % ≤ 10.0 % ( One repeat HbA1c test subject screen initial test result HbA1c ± 0.2 % cut value ) BMI ≥ 20.0 kg/m² , ≤ 35.0 kg/m² visit 1 Ages 18 65 year , inclusive ≥ 18 year old &lt; 20 year old must assent form sign dated parent guardian Target Disease Exceptions History T2DM In case subject history T2DM document history autoantibody positive GAD65 , tyrosine phosphatase IA2/IA2β , Zinc Transporter 8 ( ZnT8 ) , fast cpeptide value lower limit detection perform local central laborator , subject eligible screen Maturity onset diabetes young ( MODY ) , Pancreatic surgery , chronic pancreatitis , pancreatic disorder could result decrease βcell capacity ( eg , pancreatogenous diabetes ) Any antihyperglycemic agent use , thiazolidinediones , insulin , within 1 month prior screen visit . Use thiazolidinediones within 6 month prior screen visit . History DKA require medical intervention ( eg , emergency room visit and/or hospitalization ) within 1 month prior enrolment History hospital admission glycemic control ( either hyperglycemia hypoglycemia ) within 1 month prior enrolment Malignancy within 5 year enrolment ( exception treat basal cell treat squamous cell carcinoma ) History bladder cancer History radiation therapy low abdomen pelvis time Unstable preproliferative proliferative retinopathy ( untreated treatment ) . Physical Laboratory Test Findings Aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 3x ULN Serum total bilirubin ( TB ) &gt; 2.0 mg/dL ( 34.2 μmol/L ) . Estimated GFR ( eGFR ) Japanese Society Nephrology formula ≤ 60 mL/min/1.73m2 . Hemoglobin ≤ 11.0 g/dL ( 110 g/L ) men ; hemoglobin ≤ 10.0 g/dL ( 100 g/L ) woman . Positive hepatitis B surface antigen antihepatitis C virus antibody Abnormal Free T4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Japanese patient type 1 diabetes inadequate glycemic control insulin</keyword>
</DOC>